Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada’s innovative healthcare industry in the previous year. Nominees will be accepted from any of the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, services or healthcare IT sectors, and equal consideration will be given to contributions across any stage of development – from discovery to commercial end markets.

This year's finalists are, in alphabetical order:

• Gordon Keller, Scientific Co-founder, BlueRock Therapeutics;
• Arun Menawat, Chairman and CEO of Profound Medical; and
• Simon Pimstone, CEO of Xenon Pharmaceuticals.

The Bloom Burton Award winner will be chosen from an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism. The panel includes:

• Michael Altman, Managing Director, Perceptive Advisors
• Christopher Arendt, Head of Oncology Therapeutic Area Unit, Takeda
• Karen Bernstein, Co-Founder and Chairman, BioCentury Inc.
• Carl Gordon, Managing Partner, OrbiMed Advisors
• Dennis Purcell, Founder and Senior Advisor, Aisling Capital
• Melinda Richter, Global Head of Johnson & Johnson Innovation - JLABS
• Camille Samuels, Partner, Venrock

For more information about the finalists and the judging panel, please visit our gala webpage: https://www.bloomburton.com/ga...

We look forward to hosting you!